Generation and quality control of lipidomics data for the alzheimer's disease neuroimaging initiative cohort.

Journal Article

Alzheimer's disease (AD) is a major public health priority with a large socioeconomic burden and complex etiology. The Alzheimer Disease Metabolomics Consortium (ADMC) and the Alzheimer Disease Neuroimaging Initiative (ADNI) aim to gain new biological insights in the disease etiology. We report here an untargeted lipidomics of serum specimens of 806 subjects within the ADNI1 cohort (188 AD, 392 mild cognitive impairment and 226 cognitively normal subjects) along with 83 quality control samples. Lipids were detected and measured using an ultra-high-performance liquid chromatography quadruple/time-of-flight mass spectrometry (UHPLC-QTOF MS) instrument operated in both negative and positive electrospray ionization modes. The dataset includes a total 513 unique lipid species out of which 341 are known lipids. For over 95% of the detected lipids, a relative standard deviation of better than 20% was achieved in the quality control samples, indicating high technical reproducibility. Association modeling of this dataset and available clinical, metabolomics and drug-use data will provide novel insights into the AD etiology. These datasets are available at the ADNI repository at

Full Text

Duke Authors

Cited Authors

  • Barupal, DK; Fan, S; Wancewicz, B; Cajka, T; Sa, M; Showalter, MR; Baillie, R; Tenenbaum, JD; Louie, G; Alzheimer’s Disease Neuroimaging Initiative, ; Alzheimer’s Disease Metabolomics Consortium, ; Kaddurah-Daouk, R; Fiehn, O

Published Date

  • November 20, 2018

Published In

Volume / Issue

  • 5 /

Start / End Page

  • 180263 -

PubMed ID

  • 30457571

Pubmed Central ID

  • PMC6244184

Electronic International Standard Serial Number (EISSN)

  • 2052-4463

Digital Object Identifier (DOI)

  • 10.1038/sdata.2018.263


  • eng

Conference Location

  • England